Processa Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Processa Pharmaceuticals' CEO is George Ng, appointed in Aug 2023, has a tenure of 1.25 years. total yearly compensation is $714.03K, comprised of 22.3% salary and 77.7% bonuses, including company stock and options. directly owns 0.61% of the company’s shares, worth $23.00K. The average tenure of the management team and the board of directors is 4.2 years and 4.7 years respectively.

Información clave

George Ng

Chief Executive Officer (CEO)

US$714.0k

Compensación total

Porcentaje del salario del CEO	22.3%
Permanencia del CEO	1.3yrs
Participación del CEO	0.6%
Permanencia media de la dirección	4.2yrs
Promedio de permanencia en la Junta Directiva	4.7yrs

Actualizaciones recientes de la dirección

Recent updates

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Dec 12

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Oct 20

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

Aug 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Jul 07

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Jan 20

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Aug 26

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Jun 15

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Mar 15

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

Jan 29

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Jan 20

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de George Ng en comparación con los beneficios de Processa Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$12m
Jun 30 2024	n/a	n/a	-US$10m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$714k	US$159k	-US$11m

Compensación vs. Mercado: George's total compensation ($USD714.03K) is about average for companies of similar size in the US market ($USD655.65K).

Compensación vs. Ingresos: Insufficient data to compare George's compensation with company performance.

CEO

George Ng (50 yo)

1.3yrs

Permanencia

US$714,031

Compensación

Mr. George K. Ng, Esq. JD serves as CEO of Processa Pharmaceuticals, Inc. since August 08, 2023 and serves as its Director since August 08, 2023 and served as its Director since August 08 2023 until 2024....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
George Ng	CEO & Director	1.3yrs	US$714.03k	0.61% $ 23.0k
David Young	Co-Founder	7.8yrs	US$186.64k	2.82% $ 105.4k
Sian Bigora	Co-Founder and Chief Development & Regulatory Officer	no data	US$321.73k	0.67% $ 25.2k
Patrick Lin	Co-Founder	7.8yrs	US$1.04m	0.89% $ 33.4k
Wendy Guy	Co-Founder	7.1yrs	US$1.02m	0.36% $ 13.6k
Russell Skibsted	Chief Financial Officer	less than a year	sin datos	sin datos
Steven Cha	Senior Vice President of Clinical Research	less than a year	sin datos	sin datos

4.2yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: PCSA's management team is considered experienced (4.2 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
George Ng	CEO & Director	1.3yrs	US$714.03k	0.61% $ 23.0k
David Young	Co-Founder	7.1yrs	US$186.64k	2.82% $ 105.4k
James Neal	Independent Director	2.3yrs	US$83.00k	0.022% $ 829.3
John Devane	Member of Medical & Scientific Advisory Board	4.7yrs	sin datos	sin datos
Justin Yorke	Independent Chairman of Board	7.3yrs	US$54.00k	0.11% $ 4.3k
James Shipley	Member of Medical & Scientific Advisory Board	4.7yrs	sin datos	sin datos
Stuart Madden	Member of Medical & Scientific Advisory Board	2.1yrs	sin datos	sin datos
Khoso Baluch	Independent Director	2.3yrs	US$83.00k	0.043% $ 1.6k
Geraldine Pannu	Independent Director	4.8yrs	US$54.00k	0.088% $ 3.3k

4.7yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: PCSA's board of directors are considered experienced (4.7 years average tenure).

Processa Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Processa Pharmaceuticals, Inc. Announces CFO Changes

Processa Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2024

Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research

Co-Founder recently bought US$51k worth of stock

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals, Inc. Appoints George Ng as Chief Executive Officer

Recent updates

Processa Pharmaceuticals, Inc. Provides Updates on its Product Pipeline

Processa Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals, Inc. Announces Positive Preclinical Data for NGC-IRI

New major risk - Financial position

Processa Pharmaceuticals, Inc. Announces FDA Clearance of IND Application for A Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

Processa Pharmaceuticals, Inc. Announces CFO Changes

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.

Processa Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2024

Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research

Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial

New major risk - Shareholder dilution

Co-Founder recently bought US$51k worth of stock

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.99989 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $14.35 million.

Processa Pharmaceuticals, Inc. Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety over Capecitabine

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals, Inc. Provides Data Update Supporting A Potential Personalized Treatment Approach for Improved Cancer Care

Processa Pharmaceuticals, Inc. Appoints George Ng as Chief Executive Officer

New major risk - Share price stability

New major risk - Market cap size

Processa Pharmaceuticals, Inc. Announces to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Positive Gastric Emptying Results from its Pcs12852 Phase 2A Trial in Patients

Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Processa Pharmaceuticals, Inc. Provides Update on Enrollment Across All Clinical Programs

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Board Changes

Processa Pharmaceuticals, Inc. Elects Khoso Baluch as Director

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc., Annual General Meeting, Jul 11, 2022

Price target decreased to US$15.00

Processa Pharmaceuticals, Inc. Doses First Patient in Amended Phase 1B Protocol for Pcs6422 Combined with Capecitabine

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer

Co-Founder recently bought US$77k worth of stock

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Processa Pharmaceuticals, Inc. Announces First Patient Dosed in Its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Processa Pharmaceuticals, Inc. Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Processa Pharmaceuticals, Inc. announced that it has received $10.238773 million in funding

New 90-day high: US$10.89

Processa Pharmaceuticals, Inc. announced that it expects to receive $10.238773 million in funding

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Processa Pharmaceuticals, Inc. Announces Executive Changes

Processa Pharmaceuticals, Inc. Appoints R. Michael Floyd as Chief Operating Officer

Co-Founder recently bought US$125k worth of stock

Processa Pharmaceuticals, Inc. has completed an IPO in the amount of $19.2 million.

New 90-day low: US$3.95

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad